JP2017510661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510661A5 JP2017510661A5 JP2017504616A JP2017504616A JP2017510661A5 JP 2017510661 A5 JP2017510661 A5 JP 2017510661A5 JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017510661 A5 JP2017510661 A5 JP 2017510661A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- antibody
- methyl
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LSHWLXVHVUSFGB-KRLZFLGXSA-N CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](CC2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC(C[C@@H]1N(C)CC[C@@H](C)C1)=O Chemical compound CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](CC2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC(C[C@@H]1N(C)CC[C@@H](C)C1)=O LSHWLXVHVUSFGB-KRLZFLGXSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978460P | 2014-04-11 | 2014-04-11 | |
| US61/978,460 | 2014-04-11 | ||
| PCT/US2015/025235 WO2015157594A1 (en) | 2014-04-11 | 2015-04-10 | Tubulysin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510661A JP2017510661A (ja) | 2017-04-13 |
| JP2017510661A5 true JP2017510661A5 (enExample) | 2018-05-24 |
Family
ID=54264545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504616A Pending JP2017510661A (ja) | 2014-04-11 | 2015-04-10 | ツブリシン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9427479B2 (enExample) |
| EP (1) | EP3129362A4 (enExample) |
| JP (1) | JP2017510661A (enExample) |
| KR (1) | KR20160142392A (enExample) |
| CN (1) | CN106458942A (enExample) |
| AR (1) | AR100006A1 (enExample) |
| AU (1) | AU2015243379B2 (enExample) |
| CA (1) | CA2945318A1 (enExample) |
| CL (1) | CL2016002548A1 (enExample) |
| EA (1) | EA032203B1 (enExample) |
| IL (1) | IL247822A0 (enExample) |
| MA (1) | MA39862A (enExample) |
| MX (1) | MX2016013373A (enExample) |
| NZ (1) | NZ725131A (enExample) |
| PH (1) | PH12016501995A1 (enExample) |
| SG (1) | SG11201608203RA (enExample) |
| TW (1) | TW201625662A (enExample) |
| UY (1) | UY36075A (enExample) |
| WO (1) | WO2015157594A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR100006A1 (es) * | 2014-04-11 | 2016-08-31 | Medimmune Llc | Derivados de tubulisina |
| KR20160143808A (ko) | 2014-04-11 | 2016-12-14 | 메디뮨 엘엘씨 | 이중특이적 her2 항체 |
| SG11201706820RA (en) | 2015-02-25 | 2017-09-28 | Univ Rice William M | Desacetoxytubulysin h and analogs thereof |
| RU2710194C9 (ru) | 2015-11-10 | 2020-09-14 | МЕДИММЬЮН, ЭлЭлСи | Связывающие молекулы, специфичные в отношении asct2, и их применения |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017096311A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017134547A1 (en) * | 2016-02-01 | 2017-08-10 | Pfizer Inc. | Tubulysin analogs and methods for their preparation |
| UA127341C2 (uk) | 2016-04-15 | 2023-07-26 | Мекроудженікс, Інк. | Виділена b7-н3-зв'язувальна молекула |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| KR20250009550A (ko) | 2017-08-01 | 2025-01-17 | 메디뮨 엘엘씨 | Bcma 단클론 항체-약물 접합체 |
| IL317268A (en) | 2017-12-31 | 2025-01-01 | Hangzhou Dac Biotech Co Ltd | Conjugation of a tubulin analog with branched linkers |
| CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化（上海）新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
| AU2019403554B2 (en) | 2018-12-21 | 2025-07-24 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物 |
| MX2021015887A (es) * | 2019-06-24 | 2022-03-22 | Hangzhou Dac Biotech Co Ltd | Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados. |
| CN115867563B (zh) * | 2020-06-24 | 2025-06-27 | 里珍纳龙药品有限公司 | 微管溶素及蛋白质-微管溶素偶联物 |
| CR20230146A (es) | 2020-09-11 | 2023-06-07 | Medimmune Ltd | Moléculas de unión a b7-h4 terapéuticas |
| MX2024005712A (es) | 2021-11-10 | 2024-05-24 | Astrazeneca Ab | Moleculas de anticuerpo y conjugados. |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| IL317733A (en) | 2022-06-27 | 2025-02-01 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| WO2006063135A2 (en) * | 2004-12-09 | 2006-06-15 | Eisai R & D Management Co., Ltd. | Tubulin isotype screnning in cancer therapy using hemiasterlin analogs |
| IT1394860B1 (it) * | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| SI2780039T1 (en) * | 2011-11-17 | 2018-06-29 | Pfizer Inc. | Cytotoxic peptides and their conjugates between the antibody and the drug |
| US20130224228A1 (en) * | 2011-12-05 | 2013-08-29 | Igenica, Inc. | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods |
| AU2014216539B2 (en) * | 2013-02-14 | 2017-03-23 | Bristol-Myers Squibb Company | Tubulysin compounds, methods of making and use |
| AR100006A1 (es) * | 2014-04-11 | 2016-08-31 | Medimmune Llc | Derivados de tubulisina |
| KR20160143808A (ko) * | 2014-04-11 | 2016-12-14 | 메디뮨 엘엘씨 | 이중특이적 her2 항체 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
-
2015
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko not_active Withdrawn
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en not_active Ceased
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
-
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510661A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| NZ604007A (en) | Monoclonal antibodies against her2 epitope | |
| JP2019501204A5 (enExample) | ||
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| JP2017506227A5 (enExample) | ||
| JP2018530554A5 (enExample) | ||
| RU2014138474A (ru) | Новые модуляторы и способы применения | |
| MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MY149159A (en) | Method for treating joint damage | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2017506217A5 (enExample) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| JP2018512443A5 (enExample) | ||
| JP2016523810A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2012500814A5 (enExample) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2017506234A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| WO2015069922A3 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |